PHASE III TRIAL OF SALVAGE STEREOTACTIC RADIOSURGERY (SRS) OR SRS + HIPPOCAMPALAVOIDANT WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR FIRST OR SECOND DISTANT BRAIN RELAPSE AFTER UPFRONT SRS WITH BRAIN METASTASIS VELOCITY ≥4 BRAIN METASTASES/YEAR

Date Added
August 4th, 2022
PRO Number
Pro00122545
Researcher
Charlotte Rivers

List of Studies


Keywords
Cancer/Brain
Summary

This study is for men or women who received stereotactic radiosurgery to treat cancer that spread to their brain, and now the cancer has returned in other areas of the brain. This study is being done to see if by adding radiation therapy called whole-brain radiation therapy that avoids the hippocampus to preserver memory plus medication approved to treat dementia can extend these patients lives.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer

Date Added
June 23rd, 2021
PRO Number
Pro00110550
Researcher
Charlotte Rivers

List of Studies


Keywords
Cancer, Cancer/Brain, Cancer/Lung
Summary

This study is for participants that have been diagnosed with small cell lung cancer, that has spread to the brain. The purpose of this study is to see if high dose radiation therapy delivered only to the small areas of brain cancer and avoiding the surrounding normal brain tissue, called stereotactic radiosurgery (SRS), decrease side effects related to memory and thinking compared to radiation to the entire brain, called, whole-brain radiation therapy (WBRT) that avoids the hippocampus but treats all of the brain tissue along with a drug that helps preserve memory and thinking called memantine. Participants can expect to be on this study for up to 6 months, depending on what treatment they receive (SRS alone or HA-WBRT with memantine). Participants will then be followed every 2 to 3 months for at least 1 year after study completion and then every 6 months for their lifetime or until disease progression.

Institution
MUSC
Recruitment Contact
Lydia Moats, Research Coordinator
864-725-7125
lydia.moats@selfregional.org



-- OR --